Compugen to Collaborate with Teva on Toxicity Biomarker Discovery | GenomeWeb
NEW YORK (GenomeWeb News) - Compugen today said it has signed a collaboration with Teva Pharmaceuticals to discovery biomarkers that could predict nephrotoxicity.
 
The agreement also may be expanded to include biomarker development for hepatoxicity and cardiotoxicity, Compugen said.
 
Under the agreement, Compugen will use its computational tools and nucleic acid testing technologies to analyze biological samples collected by Teva in a preclinical study.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.